Increasing mupirocin resistance of Staphylococcus aureus in CAPD--should it continue to be used as prophylaxis?
This editorial summarizes the mechanisms of mupirocin resistance and the conditions that promote its development. While there is increasing evidence that high-level mupirocin resistance is developing during systematic use of mupirocin as prophylaxis against Staphylococcus aureus, the appearance of resistance does not preclude the beneficial effect of regular prophylaxis. Vigilance has to be exercised to notice larger-scale resistance that may require limiting the use of mupirocin.
Conly
John M
JM
Vas
Stephen
S
D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D019072:Antibiotic Prophylaxis / Q000009:adverse effects*; D024881:Drug Resistance, Bacterial / Q000502:physiology*; D006801:Humans; D016712:Mupirocin / Q000627:therapeutic use*; D010531:Peritoneal Dialysis, Continuous Ambulatory / Q000009:adverse effects*; D013203:Staphylococcal Infections / Q000209:etiology* / Q000503:physiopathology / Q000517:prevention & control*; D013211:Staphylococcus aureus / Q000187:drug effects* / Q000502:physiology*
D000900:Anti-Bacterial Agents; D016712:Mupirocin